Quantcast
Home > Quotes > VCEL

Vericel Corporation Common Stock (VCEL) Quote & Summary Data

VCEL 
$14.05
*  
0.65
4.85%
Get VCEL Alerts
*Delayed - data as of Sep. 19, 2018  -  Find a broker to begin trading VCEL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VCEL Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
15
Today's High / Low
$ 14.20 / $ 13.35
Share Volume
777,297
50 Day Avg. Daily Volume
964,729
Previous Close
$ 13.40
52 Week High / Low
$ 14.75 / $ 3.30
Market Cap
600,306,693
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.47

Intraday Chart

Shares Traded

Share Volume:
777,297
50 Day Avg. Daily Volume:
964,729

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.48

Trading Range

The current last sale of $14.05 is 325.76% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 14.20 $ 14.75
 Low: $ 13.35 $ 3.30

Company Description (as filed with the SEC)

Vericel Corporation is a leader in advanced cell therapies for the sports medicine and severe burn care markets, and a developer of patient-specific expanded cell therapies for use in the treatment of patients with severe diseases and conditions. We currently have two marketed autologous cell therapy products in the United States. MACIĀ® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults that was approved by the U.S. Food and Drug Administration (FDA) on December 13, 2016. The first shipment and implantation of MACI occurred on January 31, 2017. At the end of the second quarter, we removed MACI's predecessor, CarticelĀ® (autologous cultured chondrocytes), from the market.  ... More ...  


Risk Grade

Where does VCEL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.35
Open Date:
Sep. 19, 2018
Close Price:
$ 13.40
Close Date:
Sep. 19, 2018

Consensus Recommendation

Analyst Info